Puma Biotechnology Inc (PBYI) 13F Filing Data & Analysis (Q2 2026)

PBYI ranks #3479 out of 37501 tracked stocks by institutional interest — one of the most closely watched names in our coverage.

PBYI is a disclosed holding of Jim Simons (Renaissance Technologies), one of the tracked superinvestors on AlphaSMO — it makes up 0.0% of that fund's own 13F portfolio.

PBYI is a top-conviction position for Acorn Capital Advisors, LLC — at 9.1% of their entire disclosed 13F portfolio, it's one of their largest single bets, not just a passing allocation.

Lsv Asset Management has added to its PBYI position for two straight quarters, increasing it by $10.7M to reach $13.1M today.

WINTON GROUP Ltd has trimmed its PBYI position for two straight quarters, cutting it by $249.6K while still holding $328.5K.

PBYI is down 1.7% today, but institutions show net buying of $9.5M this quarter — a divergence between today's price move and the underlying institutional flow.

PBYI posted net income of $26.7M over the trailing twelve months, and currently trades at a P/E of 17.4.

• Profitable — net income of $26.7M over the trailing twelve months
• Revenue declined 2.9% year over year
• Net income declined year over year, from $48.5M to $26.7M
• Generated $41.8M in positive operating cash flow
• Current ratio of 2.00x — enough short-term assets to cover short-term liabilities
• Liabilities run 0.66x equity — within a conventional range